New drugs on the horizon: Matrix metalloproteinase inhibitors

Oncologist

Volumn 3, Issue 4, 1998, Pages 271-274

  Rothenberg, Mace L ^a   Nelson, Amy R ^a   Hande, Kenneth R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; BILIRUBIN; BUTYRIC ACID DERIVATIVE; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CGS 27023A; COLLAGEN; COLLAGENASE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GELATINASE; GEMCITABINE; GLYCOPROTEIN; GROWTH FACTOR; HYDROXAMIC ACID DERIVATIVE; LIVER ENZYME; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MITOXANTRONE; PACLITAXEL; PLASMA PROTEIN; PREDNISONE; PRINOMASTAT; PROSTATE SPECIFIC ANTIGEN; PROTEOGLYCAN; STROMELYSIN; TANOMASTAT; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTHRALGIA; CLINICAL TRIAL; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; MUSCLE STIFFNESS; MYALGIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RASH; REVIEW; THROMBOCYTOPENIA; TUMOR;

EID: 0031657033     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.3-4-271     Document Type: Review

References (16)

1. Powell WC, Matrisian LM. Complex roles of matrix metalloproteinases in tumor progression. In: Gunthert U, Birchmeier W, eds. Attempts to Understand Metastasis Formation I: Metastasis-Related Molecules. Berlin: Springer-Verlag, 1996:1-21.
2. Harris AL. Metalloproteinase inhibitors. Ann Oncol 1998;9(suppl 2):11a.
3. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-1270.
4. Cochrane R, Davies E, Roy M et al. MDA231s acquire an antiogenic advantage by inducing matrix metalloproteinase secretion and activation by normal breast fibroblasts. Proc Am Assoc Cancer Res 1998;30:42a.
5. Beattie GJ, Young HA, Smyth JF. Phase I study of intra-peritoneal metalloproteinase inhibitor BB-94 in patients with malignant ascites. Ann Oncol 1994;5(suppl 2):72a.
6. Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 1997;75:69-75.
7. Millar AW, Brown PD, Moore J et al. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharmacol 1998;45:21-26.
8. Rasmussen H, Rugg T, Brown P et al. A 371 patient meta-analysis of studies of marimastat in patients with advanced cancer. Proc Am Soc Clin Oncol 1997;16:429a.
9. Zaknoen S, Wolff R, Cox C et al. Marimastat in advanced progressive colorectal cancer - a dose-finding study. Proc Am Soc Clin Oncol 1997;16:273a.
10. Malfetano J, Teng N, Barter J et al. Marimastat in patients with advanced cancer of the ovary - a dose-finding study. Proc Am Soc Clin Oncol 1997;16:373a.
11. Boasberg P, Harbaugh BL, Eisenberger M et al. Marimastat in patients with hormone refractory prostate cancer: a dose-finding study. Proc Am Soc Clin Oncol 1997;16:316a.
12. Rosemurgy A, Harris J, Langleben A et al. Marimastat, a novel matrix metalloproteinase inhibitor in patients with advanced carcinoma of the pancreas. Proc Am Soc Clin Oncol 1996;15:207a.
13. Evans J, Bramhall S, Carmichael J et al. A phase II study of marimastat in advanced pancreatic cancer. Ann Oncol 1996;7(suppl 5):51a.
14. Adams M, Thomas H. A phase I study of the matrix metalloproteinase inhibitor, marimastat, administered concurrently with carboplatin, to patients with relapsed ovarian cancer. Proc Am Soc Clin Oncol 1998;17:217a.
15. Hande K, Wilding G, Ripple G et al. A phase I trial of AG3340, a matrix metalloproteinase inhibitor, in patients having advanced cancer. Ann Oncol 1998;9(suppl 2):74a.
16. Wilding G, Small E, Ripple G et al. Phase I study of AG3340, a matrix metalloproteinase inhibitor, in combination with mitoxantrone/prednisone in patients having advanced prostate cancer. Ann Oncol 1998;9(suppl 2):74a.